To note that Keap1 protein, the main regulator of NRF2 degradation, is evenly expressed in APL n = 8 (0.91 ± 0.3) and AML n = 7 (0.99 ± 0.2) patients’ samples (Figure 1c), hence a different player is involved. This evidence concerns the gene KEAP1 and acute promyelocytic leukemia.